These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26046986)

  • 1. Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer´s Disease.
    Jiang N; Leithold LH; Post J; Ziehm T; Mauler J; Gremer L; Cremer M; Schartmann E; Shah NJ; Kutzsche J; Langen KJ; Breitkreutz J; Willbold D; Willuweit A
    PLoS One; 2015; 10(6):e0128553. PubMed ID: 26046986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic properties of tandem d-peptides designed for treatment of Alzheimer's disease.
    Leithold LH; Jiang N; Post J; Niemietz N; Schartmann E; Ziehm T; Kutzsche J; Shah NJ; Breitkreutz J; Langen KJ; Willuweit A; Willbold D
    Eur J Pharm Sci; 2016 Jun; 89():31-8. PubMed ID: 27086111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase of Positive Net Charge and Conformational Rigidity Enhances the Efficacy of d-Enantiomeric Peptides Designed to Eliminate Cytotoxic Aβ Species.
    Ziehm T; Brener O; van Groen T; Kadish I; Frenzel D; Tusche M; Kutzsche J; Reiß K; Gremer L; Nagel-Steger L; Willbold D
    ACS Chem Neurosci; 2016 Aug; 7(8):1088-96. PubMed ID: 27240424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surprisingly high stability of the Aβ oligomer eliminating all-d-enantiomeric peptide D3 in media simulating the route of orally administered drugs.
    Elfgen A; Santiago-Schübel B; Gremer L; Kutzsche J; Willbold D
    Eur J Pharm Sci; 2017 Sep; 107():203-207. PubMed ID: 28711713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic Properties of a Novel D-Peptide Developed to be Therapeutically Active Against Toxic β-Amyloid Oligomers.
    Leithold LH; Jiang N; Post J; Ziehm T; Schartmann E; Kutzsche J; Shah NJ; Breitkreutz J; Langen KJ; Willuweit A; Willbold D
    Pharm Res; 2016 Feb; 33(2):328-36. PubMed ID: 26381279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer's Disease.
    Schartmann E; Schemmert S; Niemietz N; Honold D; Ziehm T; Tusche M; Elfgen A; Gering I; Brener O; Shah NJ; Langen KJ; Kutzsche J; Willbold D; Willuweit A
    J Alzheimers Dis; 2018; 64(3):859-873. PubMed ID: 29966196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood-brain barrier penetration of an Aβ-targeted, arginine-rich, d-enantiomeric peptide.
    Jiang N; Frenzel D; Schartmann E; van Groen T; Kadish I; Shah NJ; Langen KJ; Willbold D; Willuweit A
    Biochim Biophys Acta; 2016 Nov; 1858(11):2717-2724. PubMed ID: 27423267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's Disease transgenic mice.
    Aileen Funke S; van Groen T; Kadish I; Bartnik D; Nagel-Steger L; Brener O; Sehl T; Batra-Safferling R; Moriscot C; Schoehn G; Horn AH; Müller-Schiffmann A; Korth C; Sticht H; Willbold D
    ACS Chem Neurosci; 2010 Sep; 1(9):639-48. PubMed ID: 22778851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of Alzheimer's disease amyloid plaque load in transgenic mice by D3, A D-enantiomeric peptide identified by mirror image phage display.
    van Groen T; Wiesehan K; Funke SA; Kadish I; Nagel-Steger L; Willbold D
    ChemMedChem; 2008 Dec; 3(12):1848-52. PubMed ID: 19016284
    [No Abstract]   [Full Text] [Related]  

  • 10. All
    Bocharov EV; Gremer L; Urban AS; Okhrimenko IS; Volynsky PE; Nadezhdin KD; Bocharova OV; Kornilov DA; Zagryadskaya YA; Kamynina AV; Kuzmichev PK; Kutzsche J; Bolakhrif N; Müller-Schiffmann A; Dencher NA; Arseniev AS; Efremov RG; Gordeliy VI; Willbold D
    J Med Chem; 2021 Nov; 64(22):16464-16479. PubMed ID: 34739758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease.
    Dammers C; Yolcu D; Kukuk L; Willbold D; Pickhardt M; Mandelkow E; Horn AH; Sticht H; Malhis MN; Will N; Schuster J; Funke SA
    PLoS One; 2016; 11(12):e0167432. PubMed ID: 28006031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transport of Alzheimer disease amyloid-beta-binding D-amino acid peptides across an in vitro blood-brain barrier model.
    Liu H; Funke SA; Willbold D
    Rejuvenation Res; 2010; 13(2-3):210-3. PubMed ID: 19954305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer's disease.
    Schartmann E; Schemmert S; Ziehm T; Leithold LHE; Jiang N; Tusche M; Joni Shah N; Langen KJ; Kutzsche J; Willbold D; Willuweit A
    Eur J Pharm Sci; 2018 Mar; 114():93-102. PubMed ID: 29225107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreasing oxidative stress and neuroinflammation with a multifunctional peptide rescues memory deficits in mice with Alzheimer disease.
    Zhou WW; Lu S; Su YJ; Xue D; Yu XL; Wang SW; Zhang H; Xu PX; Xie XX; Liu RT
    Free Radic Biol Med; 2014 Sep; 74():50-63. PubMed ID: 24960578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QIAD assay for quantitating a compound's efficacy in elimination of toxic Aβ oligomers.
    Brener O; Dunkelmann T; Gremer L; van Groen T; Mirecka EA; Kadish I; Willuweit A; Kutzsche J; Jürgens D; Rudolph S; Tusche M; Bongen P; Pietruszka J; Oesterhelt F; Langen KJ; Demuth HU; Janssen A; Hoyer W; Funke SA; Nagel-Steger L; Willbold D
    Sci Rep; 2015 Sep; 5():13222. PubMed ID: 26394756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo staining characteristics of small, fluorescent, Abeta42-binding D-enantiomeric peptides in transgenic AD mouse models.
    van Groen T; Kadish I; Wiesehan K; Funke SA; Willbold D
    ChemMedChem; 2009 Feb; 4(2):276-82. PubMed ID: 19072935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro and In Vivo Efficacies of the Linear and the Cyclic Version of an All-d-Enantiomeric Peptide Developed for the Treatment of Alzheimer's Disease.
    Schemmert S; Camargo LC; Honold D; Gering I; Kutzsche J; Willuweit A; Willbold D
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease.
    Kim HD; Tahara K; Maxwell JA; Lalonde R; Fukuiwa T; Fujihashi K; Van Kampen KR; Kong FK; Tang DC; Fukuchi K
    J Gene Med; 2007 Feb; 9(2):88-98. PubMed ID: 17219449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structures of the amyloid β-peptides Aβ1-40 and Aβ1-42 as influenced by pH and a D-peptide.
    Olubiyi OO; Strodel B
    J Phys Chem B; 2012 Mar; 116(10):3280-91. PubMed ID: 22300010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripherally Applied Synthetic Tetrapeptides HAEE and RADD Slow Down the Development of Cerebral β-Amyloidosis in AβPP/PS1 Transgenic Mice.
    Tsvetkov PO; Cheglakov IB; Ovsepyan AA; Mediannikov OY; Morozov AO; Telegin GB; Kozin SA
    J Alzheimers Dis; 2015; 46(4):849-53. PubMed ID: 26402624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.